With the increasing availability of facilities for IHC testing and also the affordable costs, the evaluation of estrogen receptor, progesterone receptor, and HER2/neu receptor status has become a standard routine in the management of breast carcinoma. This evidence concerns the gene ERBB2 and breast carcinoma.